Abstract
Dipeptidyl peptidase IV (DPP-IV) inhibition has the potential to become a valuable therapy for type 2 diabetes. We report the first use of solid-phase synthesis in the discovery of a new DPP-IV inhibitor class and a solution-phase synthesis that is practical up to the multikilogram scale. One compound, NVP-DPP728 (2), is profiled as a potent, selective, and short-acting DPP-IV inhibitor that has excellent oral bioavailability and potent antihyperglycemic activity.
MeSH terms
-
Administration, Oral
-
Animals
-
Biological Availability
-
Caco-2 Cells
-
Dipeptidyl Peptidase 4 / metabolism*
-
Enzyme Inhibitors / chemical synthesis*
-
Enzyme Inhibitors / pharmacology
-
Glucose Tolerance Test
-
Humans
-
Hypolipidemic Agents / chemical synthesis*
-
Hypolipidemic Agents / pharmacology
-
Macaca fascicularis
-
Male
-
Nitriles / chemical synthesis*
-
Nitriles / pharmacology
-
Protease Inhibitors / chemical synthesis*
-
Protease Inhibitors / pharmacology
-
Pyrrolidines / chemical synthesis*
-
Pyrrolidines / pharmacology
-
Rats
-
Rats, Sprague-Dawley
-
Structure-Activity Relationship
Substances
-
1-(((2-((5-cyanopyridin-2-yl)amino)ethyl)amino)acetyl)-2-cyano-(S)-pyrrolidine
-
Enzyme Inhibitors
-
Hypolipidemic Agents
-
Nitriles
-
Protease Inhibitors
-
Pyrrolidines
-
Dipeptidyl Peptidase 4